Matrix metalloproteinase (MMP) expression and production are associated with advanced-stage tumor and contribute to tumor progression, invasion and metastases. The current study was designed to determine the expression and production of MMP-2 (gelatinase A) and MMP-9 (gelatinase B) by human lymphoid tumor cells. Changes in expression and production were also investigated during tumor progression of multiple myeloma and mycosis fungoides. In situ hybridization analysis revealed that lymphoblastic leukemia B cells (SB cell line), multiple myeloma (MM) cells (U266 cell line) and lymphoblastic leukemia T cells (CEM and Jurkat cell lines) express constitutively the mRNA for MMP-2 and/or MMP-9. We demonstrated by gelatin-zymography of cell culture medium that both enzymes were secreted in their cleaved (activated) form. In situ hybridization of bone marrow plasma cells and gelatin-zymography of the medium showed that patients with active MM (diagnosis, relapse, leukemic progression) express higher levels of MMP-2 mRNA and protein than patients with non-active MM (complete/objective response, plateau) and with monoclonal gammopathies of undetermined significance (MGUS). MMP-9 expression and secretion was similar in all patient groups. In patients with mycosis fungoides (MF), the expression of MMP-2 and MMP-9 mRNAs was significantly upregulated with advancing stage, in terms of lesions both positive for one of two mRNAs and with the greatest intensity of expression. Besides MF cells, the MMP-2 and/or MMP-9 mRNAs were expressed by some stromal cell populations (microvascular endothelial cells, fibroblasts, macrophages), suggesting that these cells cooperate in the process of tumor invasion. Our studies identify MMPs as an important class of proteinases involved in the extracellular matrix (ECM) degradation by human lymphoid tumors, and suggest that MMPs inhibitors may lead to important new treatment for their control.
INTRODUCTION
Many enzyme systems are involved in extracellular proteolytic events. Enzymes belong to one of two families, namely the serine proteases in particular plasminogen activator (PA)/plasmin enzymes and the matrix metalloproteinases (MMPs) (Mignatti and Rifkin, 1993) . MMPs are a family of closely related zinc-endopeptidases whose principal function is the degradation of extracellular matrix (ECM) components during normal embryo development, morphogenesis and tissue remodelling. They are secreted as zymogen (activated extracellularly), and divided into three subgroups based on the substrate preference: the interstitial collagenases, stromelysin and gelatinases (type IV collagenases), althought all of them recognize overlapping substrate specificity (Massova et al., 1998) .
Type IV collagenases include type IV 72 kDa (MMP-2 or gelatinase A) and 92 kDa (MMP-9 or gelatinase B) enzymes. Both MMP-2 and MMP-9 facilitate invasion and metastases because they degrade type IV, V, VII and X collagens as well as fibronectin (Mignatti and Rifkin, 1993; Massova et al., 1998) which are major constituents of the interstitial stroma and the subendothelial basement membrane ECM. Studies in animal models clearly demonstrated a positive correlation between MMP expression, invasive behavior and metastatic potential (Krane, 1994; Coussens and Werb, 1996; Stetler-Stevenson et al., 1997; Kanayama et al. 1998 ).
MMPs production in vivo and in vitro is increased in response to angiogenic agents (Coussen and Werb, 1996) . In some conditions, such as diabetic retinopathy, the involvement of proteinases may be confined to the process of angiogenesis (Folkman, 1995) ; in others, such as cancer and rheumatoid arthritis (Gordon et al., 1993; Bottomley et al., 1998) , proteinase activity is thought to be an integral part of generalized tissue remodelling, as well as of the formation of new blood vessels. Inhibition of MMP results in decreased invasion and metastasis of malignant cell lines (Mignatti and Rifkin, 1993 ; Krane, 1994) . (Machein and Conca, 1997; Amorino and Hoover, 1998) . Lymphoid cell extravasation into perivascular tissues during inflammation involves transmigration through the endothelial cell layer and basement membrane, and employement of adhesion mechanisms prior to degradation of the ECM, which are similar to the process of extravasation adopted by metastatic cells (Weeks et al., 1993; Madri et al., 1996; Di Girolamo et al., 1998; Trocme et al., 1998) .
In the present study, we investigated human lymphoid tumor cells of B-cell and T-cell lineage for their invasive potential in well-defined clinical models of tumor progression.
RESULTS
MMP-2 and MMP-9 Expression and Production by Human Lymphoid Tumor Cells SB (B-cell lymphoblastic leukemia), U266 (multiple myeloma), CEM and Jurkat (T-cell lymphoblastic leukemia) cell lines were evaluated for expression of MMP-2 and MMP-9 mRNA by in situ hybridization (Fig. 1 ). As summarized in Table I , SB and U266 cells co-expressed the mRNAs. The signal intensity for both mRNAs was similar in the B-lymphoblastic leukemia cell line SB, while U266 cells showed a more intense MMP-2 mRNA-related signal than that of MMP-9. The T-cell lymphoblastic leukemia cell lines CEM and Jurkat expressed only MMP-2 mRNA. The mRNAs were activated, given the fact that the enzymes were secreted into the cell culture conditioned medium (CM) and detected by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) gelatin-zymography (Fig 2) . MMP-2 and MMP-9 gave rise to gelatinolytic bands with an apparent Mr of 62 kDa and 88 kDa respectively (panel A), indicating that both enzymes were present in their cleaved, activated form (Huhtala et al., 1991 As shown in Fig. 3 , bone marrow plasma cells expressed the MMP-2 and MMP-9 mRNA (panels A to G), whereas in plasma cells from a control subject the MMP-2 mRNA was absent (panel H) or poorly expressed in some instances, as evaluated by in situ hybridization. The MMP-2 mRNA-related signal was stronger in patients with active MM (panel C) than in those with non-active MM (panel E) and with MGUS (panel G). The MMP-9 mRNA-related signal was lower than that of MMP-2 in all patient groups and overlapped between the groups (panels B, D, F). According to in situ hybridization results, SDS-PAGE gelatin-zymography of plasma cell CM (Fig. 4) showed that cells secrete activated MMP-2 (62 kDa form) and lower levels of activated MMP-9 (88 kDa form), whereas those from control subjects secrete only marginal levels of activated MMP-2 (not shown). Specifically, quantitation of MMP-2 and MMP-9 by computerized image analysis of the gelatinolytic bands showed that MMP-2 was present in CM 
MMP-2 and MMP-9 Expression by Mycosis Fungoides
To assess the ability of tumor T-cells to invade the ECM through the production of MMPs, we studied 57 biopsies of mycosis fungoides (MF) divided into three groups, i.e. patch, plaque and nodular (most advanced) groups, in accordance with histopathological diagnostic criteria for the disease (Willemze et al., 1994) . The patch stage includes tumors formed by clustered lymphoid tumor T-cells within epidermis , (E), (F) non-active MM (complete remission), (G) MGUS, and (H) from a control subject with pernicious anemia, tested with in situ hybridization for MMP-2 mRNA and MMP-9 mRNA. Note (A) numerous scattered plasma cells reactive for MMP-2 mRNA, whereas (B) fewer plasma cells were reactive for MMP-9 mRNA in the bone marrow of the active MM patient. These isolated and cytocentrifuged plasma cells were (C) strongly reactive for MMP-2 mRNA and (D) less reactive for MMP-9 mRNA. Also note (E) the weaker MMP-2 mRNA expression and (F) MMP-9 mRNA expression in the non-active MM patient, (G) the weak expression of MMP-2 mRNA in the MGUS patient and (H) no expression of MMP-2 mRNA in the control subject. Original magnifications: (A), (B), 125x, (C)-(H) 750x (see Color Plate VI at the back of this issue) and superficial dermis, whereas the plaque stage refers to clustered and scattered cells within the epidermis and dermis, and nodular stage to clustered and scattered cells within epidermis and dermis in depth. The S-phase tumor growth fraction rises in the transition from one step to the next (Willemze et al., 1994) .
The percentages of MF lesions expressing MMP-2 or MMP-9 mRNA and co-expressing both mRNAs increased in parallel with tumor progression (Table   II) . Compared to the patch stage, the plaque and even more the nodular stages gave significantly higher percentages of lesions expressing the MMP-2 mRNA (p<0.05 by chi-squared test), the MMP-9 mRNA (p<0.05) and both mRNAs (p<0.05).
The intensity of expression of MMP-2 and MMP-9 mRNA was assessed by the following score sistem: (weak intensity), 2 (moderate), 3 (strong). The frequency of tumors scoring or 2 remained fairly constant in all stages. By contrast, score 3 for both mRNAs occurred with significantly higher frequency in relation with tumor upstaging. For MMP-2 mRNA, it was detected in 18% of patch stage tumors, and in 31% and 52% of plaque and nodular stage tumors respectively (p<0.05). For MMP-9, score 3 was absent in the patch stage, whereas it was found in 13% and 31% of the plaque and nodular stage tumors respectively (p<0.05).
Histologically, the MMP-2 and MMP-9 mRNAs produced a cytoplasmic staining pattern (Fig. 5) . In all MF stages, the mRNAs were not expressed homogeneously by the entire tumor cell population, but they were expressed by single cells or nests randomly scattered in the tumor area, which gave a very heterogeneous "ground-glass-like" staining pattern (panel A-D). These RNAs were generally not expressed by identical subpopulations of tumor cells. The location of positive cells was independent of the skin structures, such as hair follicles, vessels or glands, or of the skin layer (panel C).
In all stages, the mRNAs were also found in some stromal cell populations: MMP-2 mRNA in endothelial cells of intratumor and peritumor vessels and in fibroblasts, especially located in the stroma within or around the tumor clusters (panel E), MMP- (Mignatti and Rifkin, 1993) , and since these enzymes lyse the collagens and fibronectin, which are subendothelial basement membrane and interstitial stroma ECM constituents, it is conceivable that these cells are capable of invading the stroma and the vessel wall and, partly by this way, are liable to enter the circulation. This would enable them to enter distant body sites via the same mechanisms.
As observed for tumor cells from invasive and metastatic solid tumors (Weidner, 1998) , the bone marrow plasma cells of active MM patients express and secrete high levels of MMP-2 . In some patients, sizeable levels of MMP-9 were co-expressed and co-secreted. As the progression from in situ to invasive and metastatic solid tumors is accompanied and enhanced by secretion of proteolytic enzymes (Guedez et al., 1996) .
Hence, in addition to the production of MMP-2, which is greater in active MM, and of MMP-9 by the MM plasma cells, there is a production of MMP-1 and MMP-2 by the bone marrow stromal cells stimulated (via IL-I[3?) by the plasma cells themselves.
Given the ability of MMP-1 to degrade type I collagen and of MMP-2 and MMP-9 to degrade type IV, V, VII and X collagens as well as fibronectin (Mignatti and Rifkin, 1993; Johnson et al, 1998) , the data suggest that plasma cells of active MM patients are especially capable of invading both the stroma and the basement membrane of the ECM. In addition, the degradation of ECM brings about the release of angiogenic factors that are stored inside it (Mignatti and Rifkin, 1993), though plasma cells are able to secrete angiogenic factors in active MM (Philip-Joet et al., 1995) . The proteolytic activity connected with such enzymes is thought to be responsible for the extensive permeation of organs, with destruction of their anatomical boundaries in a fashion similar to that observed in carcinomas (Kossakowska et al., 1996; 1998) .
In MF, the production of MMPs increases in step with progression stages. MMP-2 and MMP-9 mRNAs are significantly upregulated from patch to nodular stage, as indicated by more frequent tumors expressing one or both mRNAs and more frequent tumors showing the strongest expression intensity in the nodular stage. Thus, both MMPs are produced more frequently and in greater' quantities with advancing MF progression, suggesting that a more intense degradation of interstitial stroma and subendothelial basement membrane takes place with progression. This may explain the greater dissemination and deepening of MF cells into dermis as the disease progresses from the patch to the nodular stage, and accounts, together with denser angiogenesis in the plaque and even more in the nodular stage (Vacca et al., 1997) , for frequent spreading of MF cells in lymph nodes, and parenchymal organs during these stages. Finally, MMP-2 mRNA was detected in microvascular endothelial cells and fibroblasts, whereas MMP-9 mRNA was seen in a subset of macrophages. By contrast, in normal skin only MMP-2 mRNA was expressed by few microvascular endothelial cells. Thus, the expression of MMPs by stromal cells characterize the malignant condition, and agree with findings in solid tumours (Polverini, 1996; Leek et al., 1997; Ribatti et al., 1999 (Folkman, 1996; Stetler-Stevenson, 1999) could perhaps be considered in these diseases. MMP-2 and MMP-9 sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) gelatin-zymography SDS-PAGE gelatin-zymography of CM was performed to visualize the gelatinolytic activity of the secreted MMP-2 and MMP-9 (Albini et al., 1987) . Ten gg of CM proteins were applied to 7.5% SDS-PAGE gels co-polymerized with type A gelatin from porcine skin (Sigma Chemical Co., St. Louis, MO) at a final concentration of 0.6 mg/ml. After electrophoresis, gels were washed in 2.5% Triton lx for 1 h to remove SDS, incubated for 18 h at 37C and stained in 0.1% Coomassie brilliant blue. The gelatinolytic regions were observed as white bands against a blue background. The levels of MMP activity were assessed by scoring the intensity of the bands by a computerized image analysis (APPLE, Cupertino, CA).
MATERIAL AND METHODS
In Situ Hybridization of MMP-2 and MMP-9 mRNA This was performed as described previously (Vacca et al., 1997; 1998 (Huhtala et al., 1991) . Fifty percent deionized formamide, 600 mM NaC1, 80 mM TRIS, 4 mM EDTA, 10 mM dithiothreitol, lx Denhardt's Solution and 100 gg/ml salmon sperm DNA were used as hybridization medium. After washing in 2x to 0.01x SSC and in PBS, cytospins were incubated overnight at 4C with streptavidin-alkaline phosphatase conjugate (Promega Co., Madison, WI). After alkaline phosphatase activity was revealed by Western blue stabilized substrate (Promega Co.), cytospins were mounted in buffered glycerin and evaluated by two observers with a double-headed Leitz Dialux 20 photomicroscope (Leitz, Wetzlar, Germany). Cells were scored positive for the hybridization signal relative to the background signal of RNAse-treated control cytospins hybridized with the same oligonucleotides as follows: (-) , no signal; (+), detectable signal; (2+), easily visualized signal. For MF tissues, deparaffinized sections processed as described above were used. After detection of alkaline phosphatase activity by Western blue stabilized substrate (Promega Co.), sections were mounted in buffered glycerine, and then evaluated by two investigators under the photomicroscope for the extent and intensity of the hybridization signal within the tumor area. The signal was scored relative to the background signal of RNAse-treated sections hybridized with the same oligonucleotides (negative controls) as follows:
(1) weak (detectable), (2) moderate (easily visualised) or (3) strong. MF were considered positive when >10% of tumor cells gave the signal. Negative MF (scored as 0) were those with <10% of tumor cells displaying the signal. The cut-off was based on the finding that <10% of tumor cells seldom gave the signal in negative controls.
